Comparative analysis of the interleukin-28b gene alleles in patients with hepatitis C monoinfection and combined HIV/hepatitis C infection

Cover Page

Cite item

Full Text

Abstract

Aim. To identify the frequency and to perform the comparative analysis of IL-28B genotypes distribution in patients with hepatitis C (HCV) mono-infection and combined HIV/HCV infection. Methods. 101 patients (65% - males, average age 33.85±0.62 years) were included in the study. The first group (n=58) - patients with HCV mono-infection, second (n=43) - patients with combined HIV/HCV infection. Single nucleotides polymorphism at rs8099917 and rs12979860 locuses of IL-28B gene was performed using the «AmpliSens Genoscreen-IL28V-FL» reagent kit in the viral hepatitis laboratory of the molecular diagnostics department, CSRIE, Moscow. The baseline activity of HCV infection was determined by RNA-HCV viral load >400 000 copies/mL and alanine aminotransferase level (ALT). In the first group high RNA-HCV viral load (>400 000 copies/mL) was observed in 30 (51.7%) patients, mean ALT level was 72.79±9.85 U/L; in the second group high HCV-RNA viral load was detected in 35 (81.4%) patients, mean ALT level was 85.46±7.73 U/L. In the group with combined infection 26 (60.5%) of patients received antiretroviral therapy (ART); in 14 (53.8%) of them there was no detectable viral load. The median absolute number of CD4+ lymphocytes was 0.400±0.04 cells/μL, median percentage - 25.41%±2.41. In 17 (39.5%) treatment-naïve patients the viral load was low (<10 000 copies/mL), in 11 (64.8%) of these patients mean CD4+ count was 0.470±0.04 cells/μL (25.33%±2.15); the term of HIV antibodies detection was 6.89±0.53 years. The sensitivity of the PCR method for the qualitative detection of HCV-RNA was 111.1 copies/mL, quantitative - 275 copies/mL, for HIV-RNA - 150 copies/mL. Results. In patients with HCV mono-infection the rate of unfavorable IL-28B CT and TT rs12979860 genotypes and ТG and GG rs8099917 genotypes was 45 (77.6%) и 26 (44.8%) correspondingly, favorable СС rs12979860 and ТТ rs8099917 genotypes were registered in 13 (22.4%) and 32 (55.1%) patients correspondingly. In patients with HIV/HCV infection (n=43) unfavorable IL-28B CT and TT rs12979860 genotypes and ТG and GG rs8099917 genotypes were detected in 20 (46.5%) и 13 (30.2%) of cases, and favorable СС rs12979860 and ТТ rs8099917 genotypes - in 23 (53.5%) and 30 (69.8%) of cases correspondingly. Conclusion. Results show that favorable CC rs12979860 and TT rs8099917 genotypes of the IL-28B and their combination are found quite frequently in patients with mixed HCV/HIV infection, particularly in patients with HCV genotype 3, these patients also had more significant inflammatory reaction and high HCV RNA viral load compared to HCV mono-infected patients.

About the authors

V K Fazylov

Kazan State Medical University, Kazan, Russia

E R Manapova

Kazan State Medical University, Kazan, Russia

Email: elveram@yandex.ru

S V Tkacheva

Kazan State Medical University, Kazan, Russia

F M Yakupova

Kazan State Medical University, Kazan, Russia

A T Beshimov

Republican Centre for AIDS and Infectious Diseases Treating and Prevention, Kazan, Russia

References

  1. Козина А.Н., Абрамов Д.Д., Климова Е.А. и др. Возможности персонифицированного подхода к лечению гепатита С на основании разработанных генетических тестов определения варианта полиморфизма гена ИЛ-28В человека // Леч. врач. - 2011. - №10. - С. 39-43.
  2. Aparicio E., Parera M., Franco S. et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-patients // PLoS ONE. - 2010. - Vol. 5, N 10. - P. 13771.
  3. Chung R.T., Andersen J., Volberding P. et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons // N. Engl. J. Med. - 2004. - Vol. 351. - P. 451-459.
  4. Conjeevaram H.S., Fried M.W., Jeffers L.J. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 // Gastroenterology. - 2006. - Vol. 131. - P. 470-477.
  5. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. - 2009. - Vol. 461, N 7262. - P. 399-401.
  6. Hadziyannis S.J., Sette H.Jr., Morgan T.R. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose // Ann. Intern. Med. - 2004. - Vol. 140, N 5. - P. 346-355.
  7. Jeffers L.J., Cassidy W., Howell C.D. et al. Peginterferon alfa-2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1 // Hepatology. - 2004. - Vol. 39. - P. 1702-1708.
  8. Labarga P., Barreiro P., Mira J.A. et al. Impact of IL28B polymorphisms on response to peginterferon plus ribavirin in HIV-HCV coinfected patients with prior non-response or relapse // AIDS. - 2011. - Vol. 25. - P. 1131-1133.
  9. Liu C.H., Liu C.J., Lin C.L. et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicentre, randomized controlled trial // Clin. Infect. Dis. - 2008. - Vol. 47. - P. 1260-1269.
  10. McCarthy J., Li J., Thompson A. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin // Gastroenterology. - 2010. - Vol. 138. - P. 2307-2314.
  11. Rallón N.I., Naggie S., Benito J.M. et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients // AIDS. - 2010. - Vol. 24, N 8. - P. 23-29.
  12. Rallon N.I., Soriano V., Naggie S. et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin // AIDS. - 2011. - Vol. 25. - P. 1025-1033.
  13. Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study // Gastroenterology. - 2010. - Vol. 138, N 4. - P. 1338-1345.
  14. Rodriguez-Torres M., Jeffers L.J., Sheikh M.Y. et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C // N. Engl. J. Med. - 2009. - Vol. 360. - P. 257-267.
  15. Zobair M.Y., Birerdinc A., Estep M. et al. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin // J. Translat. Med. - 2012. - Vol. 10. - P. 25.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2013 Fazylov V.K., Manapova E.R., Tkacheva S.V., Yakupova F.M., Beshimov A.T.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).